{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:11:03Z","timestamp":1786990263393,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.humpath.2026.106051","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:21:20Z","timestamp":1769098880000},"page":"106051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Polymorphic central nervous system (CNS) immune deficiency\/dysregulation-associated lymphoproliferative disorders show a uniquely aggressive clinicopathologic profile compared to their extra-CNS counterparts"],"prefix":"10.1016","volume":"170","author":[{"given":"Frank Rojas","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I","family":"Nayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8325-365X","authenticated-orcid":false,"given":"Hamza","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106051_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2023.08.007","article-title":"Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds","volume":"263","author":"Kolijn","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1016\/j.humpath.2026.106051_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-animal-022513-114201","article-title":"Origin and evolution of adaptive immunity","volume":"2","author":"Boehm","year":"2014","journal-title":"Ann Rev Anim Biosci"},{"issue":"20","key":"10.1016\/j.humpath.2026.106051_bib3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.humpath.2026.106051_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106051_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101167","article-title":"Immune deficiency\/dysregulation -associated lymphoproliferative disorders. Revised classification and management","volume":"64","author":"Carbone","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.humpath.2026.106051_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/his.15342","article-title":"Genetic and immunological features of immune deficiency and dysregulation-associated lymphoproliferations and lymphomas as a basis for classification","volume":"86","author":"Dierickx","year":"2025","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.humpath.2026.106051_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.path.2023.01.008","article-title":"Immunodeficiency-associated Epstein-Barr virus-positive B-cell lymphoproliferative disorders: a review and new paradigm","volume":"16","author":"Chapman","year":"2023","journal-title":"Surg Pathol Clin"},{"issue":"11","key":"10.1016\/j.humpath.2026.106051_bib8","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12858","article-title":"A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors","volume":"14","author":"Fink","year":"2014","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.humpath.2026.106051_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00401-013-1202-x","article-title":"Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice","volume":"127","author":"Deckert","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.humpath.2026.106051_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.humpath.2026.106051_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.24834","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: an international primary central nervous system lymphoma collaborative group report","volume":"116","author":"Cavaliere","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2026.106051_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"10.1016\/j.humpath.2026.106051_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102186","article-title":"Effective management of primary central nervous system posttransplant lymphoproliferative disorder in a kidney transplant recipient using surgery and rituximab, along with a literature review","volume":"90","author":"Liu","year":"2025","journal-title":"Transpl Immunol"},{"issue":"6","key":"10.1016\/j.humpath.2026.106051_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/01.TP.0000079253.06061.52","article-title":"Primary brain lymphomas after kidney transplantation: presentation and outcome","volume":"76","author":"Snanoudj","year":"2003","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.humpath.2026.106051_bib15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.17398","article-title":"Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients","volume":"193","author":"Taj","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.humpath.2026.106051_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/N82CTQ1J0XEVEFQB","article-title":"Primary central nervous system posttransplant lymphoproliferative disorders","volume":"121","author":"Castellano-Sanchez","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2026.106051_bib17","article-title":"Post-transplant lymphoproliferative disorder (PTLD) in the US population: demographics, treatment characteristics, and survival analysis","volume":"15","author":"Ullah","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.humpath.2026.106051_bib18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"Munz","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.humpath.2026.106051_bib19","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/onco.13969","article-title":"Validation of a post-transplant lymphoproliferative disorder risk prediction score and derivation of a new prediction score using a national bone marrow transplant registry database","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2026.106051_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.709370","article-title":"Case report: successful chimeric antigen receptor T cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder","volume":"11","author":"Yan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2026.106051_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-017-0087-0","article-title":"Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients","volume":"6","author":"Bishnoi","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2026.106051_bib22","first-page":"1904","article-title":"Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression","volume":"7","author":"Gu","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.humpath.2026.106051_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.humpath.2026.106051_bib24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2026.106051_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \"methotrexate-associated lymphoproliferative disorders\" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.humpath.2026.106051_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/230173","article-title":"Posttransplant lymphoproliferative disorders","volume":"2012","author":"Ibrahim","year":"2012","journal-title":"Adv Hematol"},{"issue":"3","key":"10.1016\/j.humpath.2026.106051_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1399-0012.2005.00342.x","article-title":"Early onset post-transplant lymphoproliferative disease is associated with allograft localization","volume":"19","author":"Bakker","year":"2005","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.humpath.2026.106051_bib28","first-page":"481","article-title":"[Post-transplantation lymphomas and Epstein-Barr virus]","volume":"19","author":"Caillard","year":"1998","journal-title":"Nephrologie"},{"issue":"Suppl 1","key":"10.1016\/j.humpath.2026.106051_bib29","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1007\/s001470050368","article-title":"Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French working group","volume":"13","author":"Caillard","year":"2000","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.humpath.2026.106051_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.humpath.2026.106051_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-025-04039-4","article-title":"Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis","author":"Yoshino","year":"2025","journal-title":"Int J Hematol"},{"issue":"32","key":"10.1016\/j.humpath.2026.106051_bib32","doi-asserted-by":"crossref","first-page":"33849","DOI":"10.18632\/oncotarget.5292","article-title":"Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage","volume":"6","author":"Crane","year":"2015","journal-title":"Oncotarget"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:02:47Z","timestamp":1773090167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S0046817726000201"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106051","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymorphic central nervous system (CNS) immune deficiency\/dysregulation-associated lymphoproliferative disorders show a uniquely aggressive clinicopathologic profile compared to their extra-CNS counterparts","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106051"}}